EP0378643A4 - Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection - Google Patents

Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection

Info

Publication number
EP0378643A4
EP0378643A4 EP19890907511 EP89907511A EP0378643A4 EP 0378643 A4 EP0378643 A4 EP 0378643A4 EP 19890907511 EP19890907511 EP 19890907511 EP 89907511 A EP89907511 A EP 89907511A EP 0378643 A4 EP0378643 A4 EP 0378643A4
Authority
EP
European Patent Office
Prior art keywords
proteins
soluble
arc
treating
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890907511
Other versions
EP0378643A1 (en
Inventor
Richard A. Fisher
Robert T. Schooley
Martin S. Hirsch
Victoria A. Johnson
Bruce D. Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Biogen Inc
Original Assignee
General Hospital Corp
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Biogen Inc filed Critical General Hospital Corp
Publication of EP0378643A1 publication Critical patent/EP0378643A1/en
Publication of EP0378643A4 publication Critical patent/EP0378643A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
EP19890907511 1988-06-10 1989-06-08 Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection Withdrawn EP0378643A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20464588A 1988-06-10 1988-06-10
US204645 1988-06-10
US34108089A 1989-04-20 1989-04-20
US341080 1989-04-20

Publications (2)

Publication Number Publication Date
EP0378643A1 EP0378643A1 (en) 1990-07-25
EP0378643A4 true EP0378643A4 (en) 1990-12-27

Family

ID=26899660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890907511 Withdrawn EP0378643A4 (en) 1988-06-10 1989-06-08 Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection

Country Status (4)

Country Link
EP (1) EP0378643A4 (en)
JP (1) JPH02504641A (en)
AU (1) AU3831889A (en)
WO (1) WO1989011860A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020872D0 (en) * 1990-09-25 1990-11-07 Ml Lab Plc Pharmaceutical compositions and use thereof
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JP3134874B2 (en) * 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Use of DNA encoding T cell surface protein T4 and T4 fragment for AIDS treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO8911860A1 *
The Journal of Infectious Diseases, Vol. 159, No. 5, May 1989, pages 837-844, The University of Chicago; V.A. JOHNSON et al.: "Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine", whole article. *

Also Published As

Publication number Publication date
WO1989011860A1 (en) 1989-12-14
AU3831889A (en) 1990-01-05
JPH02504641A (en) 1990-12-27
EP0378643A1 (en) 1990-07-25

Similar Documents

Publication Publication Date Title
AU4019289A (en) Hiv protease inhibitors useful for the treatment of aids
AU6822990A (en) Hiv protease inhibitors useful for the treatment of aids
IL91843A0 (en) Hiv proteins and peptides useful in the diagnosis,prophylaxis aids or therapy of aids
EP0276279A4 (en) Composition of matter and method of immunizing against viral causative agents of aids and arc.
OA08729A (en) Agents for prophylaxis and therapy of retroviral infections.
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
IL89900A0 (en) Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
EP1034003A4 (en) Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
AU3413389A (en) Method of treating retrovirus infection
ZA886273B (en) Novel hiv proteins and peptides useful in the diagnosis,prophylaxis or therapy of aids
EP0608212A4 (en) Method of treating viral infection.
EP0378643A4 (en) Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection
AU3836489A (en) Treatment of immunodeficiency
OA09507A (en) Compositions and methods for treating or preventing AIDS ARC and HIV infection
ZA888822B (en) Agents for removing human immunodeficiency virus and/or its related compounds
OA09648A (en) Immunotherapeutic compositions for treating and preventing AIDS ARC and HIV infection
IL82702A0 (en) Use of avarone and avarol and derivatives thereof for the control of aids and arc
AP9801368A0 (en) Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection
ZA892627B (en) Hiv protease inhibitors useful for the treatment of aids
ZA896430B (en) Hiv protease inhibitors useful for the treatment of aids
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
AU1792788A (en) Rubradirin derivatives for treatment of hiv infection
AU620084C (en) HIV protease inhibitors useful for the treatment of aids
IE880770L (en) Treatment of viral infections
KR900007413A (en) Prevention of AIDS, treatment and composition for the treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19901107

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920121